References
- Zimmet PZ, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–787
- Skyler JS. Diabetes mellitus: pathogenesis and treatmant strategies. J Med Chem 2004; 47: 4112–4117
- Petersen K, Hendler R, Price I, Sobel E. Study on the mechanism of insulin resistance in obesity. Diabetes 1998; 47: 381–386
- Boden G. Obesity, free fatty acids, and insulin resistance. Curr Opin Endocrinol Diabetes 2001; 8: 235–239
- Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–850
- King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557b
- Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Jensen AF, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar. J Med Chem 2003; 46: 1306–1317
- Kjellstedt A, Oakes N, Svensson L. AZ242, a novel PPAR α/γ agonists, has potent and efficient insulin sensetzing and antidyslipidemic properties in ob/ob mice and fa/fa zucker rats. Diabetes 2001; 50(suppl. 2)A121
- Shinkai H, Onogi S, Tanaka M, Shibata T, Iwao M, Wakitani K, Uchida I. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J Med Chem 1998; 41: 1927–1933